Inhibikase
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Inhibikase and other ETFs, options, and stocks.About IKT
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company, which engages in developing protein kinase inhibitor therapeutics to modify the course of Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. It also focuses on neurodegeneration and its lead program IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Ableson Tyrosine Kinases.
CEOMilton H. Werner
CEOMilton H. Werner
Employees8
Employees8
HeadquartersAtlanta, Georgia
HeadquartersAtlanta, Georgia
Founded2008
Founded2008
Employees8
Employees8
IKT Key Statistics
Market cap13.80M
Market cap13.80M
Price-Earnings ratio-0.59
Price-Earnings ratio-0.59
Dividend yield—
Dividend yield—
Average volume31.58K
Average volume31.58K
High today—
High today—
Low today—
Low today—
Open price$2.20
Open price$2.20
Volume0.00
Volume0.00
52 Week high$4.35
52 Week high$4.35
52 Week low$0.79
52 Week low$0.79